ZYNE News and Press, Zynerba Pharmaceuticals Inc. From 05/24/23

2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...

2023-05-15 09:22:25 ET Zynerba Pharmaceuticals press release ( NASDAQ: ZYNE ): Q1 GAAP EPS of -$0.21 misses by $0.02 . $44.4 million in cash and cash equivalents at March 31, 2023; Cash runway to mid-year 2024. For further details see: Zynerba Pharmaceuticals...

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 $44.4 million in cash and cash equivalents at March 31, 2023; Cash runway to mid-year 2024 Proposal for a revers...

Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy ass...

DEVON, Pa., April 05, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of two posters at the 55 th Gatlinburg...

2023-03-28 07:52:01 ET Zynerba Pharmaceuticals press release ( NASDAQ: ZYNE ): Q4 GAAP EPS of -$0.18 in-line. As of December 31, 2022, cash and cash equivalents were $50.6 million, compared to $67.8 million as of December 31, 2021. Management believes that the Company&...

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted orphan drug designation for cannabidiol, the active ingredient in Zygel, in 22q11.2 deletion...

2023-03-13 16:34:58 ET Zynerba Pharmaceuticals ( NASDAQ: ZYNE ) on Monday said that it did not hold cash deposits or securities at embattled Silicon Valley Bank (SVB). ZYNE stock was down 2% to $0.40 after hours. SVB was taken over by U.S. regulators on Friday ...

DEVON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today issued a statement confirming that it does not hold cash deposits or ...

DEVON, Pa, March 07, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of ...